BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional

  BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap
  BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells
  Including Those for Diabetes Research

Business Wire

ALAMEDA, Calif. -- May 07, 2013

BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, today
announced the release of the enhanced LifeMap BioReagents™ portal
( featuring an improved user interface,
product descriptions, and customer support options, as well as the addition of
new PureStem™ progenitor cells to the site. These novel progenitors provide
new and unique tools for researchers to study developmental biology, tissue
genesis and regenerative medicine, demonstrating purity in culture and unique
gene expression. Among the new product offerings are novel PureStem™
progenitor cells such as the E72 cells capable of differentiating into
betatrophin-expressing adipocytes, which may be useful in diabetes research.

Via LifeMap BioReagents™, researchers in academia, research hospitals, and
biotech and pharma companies can access and purchase BioTime’s research
products, including PureStem™ human progenitor cells, PureStem™ packages,
clinical and research grade human embryonic stem cell (hES) lines, culture
media, and cell differentiation kits. As of April, the portal also offers
select recombinant proteins, including growth factors, signaling molecules,
differentiation factors, cytokines and chemokines that complement
BioTimeresearch product lines.

LifeMap BioReagents™ is integrated with LifeMap’s integrated database suite
products LifeMap Discovery™, GeneCards^® and MalaCards, thereby providing all
biomedical researchers accessing these databases a means of identifying stem
cell reagents that can enhance research and discovery efforts in a variety of
fields, including stem cell research, developmental biology, mechanisms of
various human diseases, drug discovery and therapeutic discovery and
development. According to Google Analytics, the sites have generated more than
2,000,000 unique visitors with more than 13,000,000 page views in the past 12
months. LifeMap holds an exclusive, worldwide license from Yeda Research and
Development Company Ltd., the commercial arm of theWeizmann Institute of
Science, to marketGeneCards^®(, the human gene compendium,
andMalaCards(, a database with nearly 17,000 human disease

“The diversity, purity, and scalability of PureStem™ cells combined with the
continued discovery process underway at BioTime, where novel differentiation
pathways are being defined, gives us a growing opportunity to market these
products in the research sector,” said Jeffrey Janus, Vice President of Sales
and Marketing at BioTime. “This is an exciting beginning to a new era in stem
cell research. In combination with the LifeMap integrated database suite, our
embryonic progenitors will provide researchers a unique new set of products to
make novel clinical discoveries and advance the field of regenerative

“We are pleased to continue the expansion and enhancement of our e-Commerce
portal,” statedYaron Guan-Golan, Head of Marketing at LifeMap Sciences. “Our
growing user base will have improved access to our product portfolio via
LifeMap BioReagents™. The addition of PureStem™ human progenitor lines,
including cell types targeting the hottest new research in diabetes, will
increase LifeMap BioReagents™ brand awareness and the quality of our offering
to the global biomedical research community.”

About LifeMap Sciences, Inc.

LifeMap Sciences’ ( core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
According to Google Analytics, the sites have generated more than 2,000,000
unique visitors with more than 13,000,000 page views in the past 12 months.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


BioTime, Inc.
Judith Segall, 510-521-3390 ext. 301
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
Press spacebar to pause and continue. Press esc to stop.